Latest Conference Articles

In a late-breaking abstract presented during ASH 2022, investigators found patients treated with PTCy had a significantly lower hazard of GRFS than the standard therapy group.

A recent study presented at ASH 2022 examined the safety profiles of different hormonal contraceptives for female sickle cell disease patients at risk of thromboembolism.

The advisory committee voted 3-8 against the benefit-risk profile of omecamtiv mecarbil for heart failure with reduced ejection fraction.

The treatment was superior in various secondary endpoints, included transfusion avoidance, changes from baseline in hemoglobin level, FACIT-F scores and ARC, and the rate of clinical BTH.

Data from the largest investigation of TP53 mutations in pediatric patients with acute myeloid leukemia (AML) is presented at the ASH 2022 Annual Meeting.

"There's no national guidance on how this information should be delivered back to families, which leaves it up to each state's newborn screening program to decide the best route that they see fit," Dr. Corinna Schultz explains.

New phase 2 interim data show rates of the erectile condition were halved after 26 weeks of treatment.

Dr. Stephanie Guarino's novel analysis found a significant relationship between self-efficacy in adults with SCD, and experiences of disease-related stigma.

New research presented at ASH 2022 and conducted following a Hemophilia-Related Distress Questionnaire indicated racial disparities between White and Black patients.

In her mitochondrial work, Dr. Claudia Morris made a novel discovery that wasn't discussed in her presentation at the ASH 2022 Annual Meeting.

The results show the mean change from baseline in PKDD was ‒7.19 for M/M patients, ‒4.58 for P/M patients, and ‒3.94 for mitapivat patients.

"Acute myeloid leukemia (AML) remains the most deadly disease among adults, with a five year overall survival of less than 30%," lead investigator Dr. Molly Tokaz says in an interview.

The results for emotional functioning, social functioning, and nausea and vomiting numerically favored D-Rd at several time points.

New research presented at ASH 2022 showed survival rate improvements for APL patients through a simplified treatment algorithm designed by the trial investigators.

The accurate prediction of EF trajectory phenotypes may determine personalization of prognosis and treatment in a pediatric population with acute myeloid leukemia.

New research assessed whether the T117S gene variant could be useful as a marker for predicting sickle cell disease patients' might responses to hydroxyurea treatment.

Researchers from Germany suggest the utility of platelet and absolute neutrophil counts may be misplaced in current standards for pediatric remission.

Every patient in the study was VOC-free at the time of the data cut.

A whole genomic sequencing study shows what may be influencing risk of quadruple-agent regimen response in patients receiving daratumumab.

Research into ovarian follicular density in younger female sickle cell disease patients finds no effect from exposure to hydroxyurea.

Compared with infants kept on a standard dose of hydroxyurea, those receiving escalating doses showed greater increases in HbF and HB without significant toxicity.

A study in the Dominican Republic assessed the use of dose escalation of hydroxyurea for children in a single hospital with sickle cell anemia.

Research presented at ASH 2022 examined the ages of onset of ASSC in younger sickle cell disease patients treated with hydroxyurea.

The SPHRE trial in Tanzania show significant benefit for children at high stroke risk in sub-Saharan Africa.

Updated findings from the ongoing clinical trial investigating lovo-cel in sickle cell disease and persistent anemia allude to the possibility that a contributing factor of anemia was identified.

An in vitro assessment showed the promising molecule class should be advanced toward prospective clinical trials.

The observed heterogeneity between BP-CMML cases suggested distinct clinicopathological phenotypes and the investigators integrated clinical metadata with blast immunophenotype with 59 independent features.

A total of 55 metabolites were significantly different between samples from patients with SCD at baseline and healthy control samples.